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ABSTRACT
The pleiotropic cytokine IL-6 accelerates the progression of breast cancer in a 
variety of preclinical models through the activation of the STAT3 (signal transducer 
and activator of transcription 3) signaling pathway. However, the proportion of breast 
cancers sensitive to anti-IL-6 therapies is not known. This study evaluates the efficacy 
of anti-IL-6 therapies using breast cancer patient derived xenografts (PDXs). During 
the generation of our collection of PDXs, we showed that the successful engraftment 
of tumor tissue in immunodeficient mice correlates with bad prognosis. Four PDXs out 
of six were resistant to anti-IL-6 therapies and the expression of IL-6, its receptor 
or the levels of phospho-STAT3 (the active form of the signal transducer) did not 
correlate with sensitivity. Using cell cultures established from the PDXs as well as 
samples from in vivo treatments, we showed that only tumors in which the activation 
of STAT3 depends on IL-6 respond to the blocking antibodies. Our results indicate 
that only a fraction of breast tumors are responsive to anti-IL-6 therapies. In order 
to identify responsive tumors, a functional assay to determine the dependence of 
STAT3 activation on IL-6 should be performed.
INTRODUCTION
In women, breast cancer is the most frequently 
diagnosed type of cancer and the second leading cause 
of cancer-related deaths. Despite appropriate adjuvant 
systemic therapies, up to 30% of patients will relapse. 
Tumors resistant to the first line of therapy are treated with 
multiple lines of therapy, in general with little success. 
Many new drugs are currently being developed to treat 
these recurrent breast cancers but, giving the numerous 
failures in the clinic of therapies that show efficacy in 
laboratory models, there is a pressing need for preclinical 
models as similar as possible to the real mammary tumor. 
In the last decades it has become apparent that breast 
tumors are composed of different cell populations. This 
cellular heterogeneity has been proposed responsible for 
recurrence and resistance to most therapies. Historically, 
preclinical research relied on cell lines established from 
tumor specimens. However, cell lines do not reflect 
breast cancer heterogeneity because they are frequently 
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oligoclonal and, since they propagate as monolayers 
in vitro, in conditions that differ greatly from those in 
the tumor, they are arbitrarily selected. In the 1980s, 
xenografted human tumor models, also known as patient-
derived xenografts (PDXs), emerged as an experimental 
system with many advantages over established cells 
lines. Tumor xenografts frequently maintain the cell 
differentiation and morphology, the architecture, 
molecular signatures and intratumoral heterogeneity of 
the original tumor and are considered by several authors 
predictive preclinical models [1-6].
Interleukin-6 (IL-6) is a multifunctional cytokine 
originally described as a regulator of the immune and 
inflammatory responses. IL-6 is presented by its specific 
receptor (IL-6 receptor alpha, IL6RA) to a signaling 
receptor (gp130), which is shared by other cytokines 
[7]. The complex IL-6/IL6RA/gp130 activates different 
intracellular signaling pathways, the most prominent of 
which is the JAK (Janus kinases)-STAT (signal transducer 
and activator of transcription) pathway. Of the members 
of the STAT family, STAT3 has been shown to be the most 
important for breast cancer progression [8].
The expression of IL-6 is elevated in different 
tumors of epithelial origin [9]. In breast cancer patients, 
the increase in serum IL-6 correlates with poor disease 
outcome and prognosis [10]. Accordingly, blockade of 
IL-6 signaling, through the inactivation of its signaling 
receptor (gp130), reduces the aggressiveness of breast 
cancer cells in a variety of assays [10]. Blocking antibodies 
against IL-6, or against its receptor, are in different stages 
of clinical development. In fact, anti-IL-6 antibodies have 
been recently approved to treat multicentric Castleman’s 
Disease, a rare lymphoproliferative syndrome [11]. 
The aim of this study was to establish a collection of 
breast cancer PDXs that retain the immunohistochemical 
and molecular characteristics of the original tumor, 
to assess the relationship between the engraftment of 
the tumors and the outcome of breast cancer PDXs, to 
analyze the effect of anti-IL-6 antibodies on their growth 
and develop an assay to select tumors that depend on IL-6 
signaling to grow.
RESULTS
Establishment and characterization of a collection 
of breast cancer PDXs
Out of the 137 samples implanted, 17 breast 
cancer xenografts were successfully established (12.4%). 
Successful engraftment rates were correlated with the 
status of hormone receptors, grade, histology, Ki-67 
proliferation index, stage, molecular subtype, neoadjuvant 
treatments and BRCA status (Table 1). There was also no 
correlation between engraftment and HER2 positivity, but 
when we grouped the HER2 positive patients (luminal 
B HER2+ and HER2+) then the molecular subtype was 
predictor of engraftment (p < 0.04) (data not shown). 
Successful engraftment was indicator of reduced 
overall survival and progression free survival (p < 0.0001) 
(Figure 1). Sixteen patients (11.8%) died from breast 
cancer, of which 9 (56.3%) were successfully engrafted. 
One hundred and eight patients (78,8%) remained with 
no evidence of disease, of which 102 (94.4%) failed to 
generate a PDX. The statistically significant bad prognosis 
of tumors that successfully engrafted was consistent in 
three subtypes of tumors analyzed (triple negative, HER2-
positive and luminal B) (Figure 1). Thus, in agreement 
with previous reports [4,6], our collection of breast cancer 
PDXs is enriched in aggressive tumors of poor prognosis, 
making it a useful tool to characterize therapies against the 
most deadly tumors.
Effectiveness of anti-IL-6 therapy on the growth 
of PDXs
IL-6 promotes the growth of breast cancers [12,13]. 
We have recently shown that the autocrine production 
of IL-6 by naturally occurring senescent cells fosters 
growth of a HER2-positive tumor. Accordingly, this PDX 
(referred to as PDX118 in the present manuscript) is 
sensitive to anti-IL-6 blocking antibodies [14]. 
To extend this observation we used five additional 
PDX models. In addition to another HER2-positive PDX, 
we selected four triple negative PDXs, we chose this 
subtype because it has been shown that it also depends on 
IL-6 signaling to grow [15] and it is the only subtype of 
breast cancer without targeted therapy. 
The classification of the different PDXs was 
assessed by analyzing the expression of hormone 
receptors (ER and PR) and HER2 (Figure 2A, 2C (see also 
supplementary Figure S1)). In addition, we determined 
intrinsic subtypes of breast cancer according to the levels 
of expression of selected genes. In accordance with the 
results of the immunohistochemical analysis, PDX50, 154, 
243 and 377 were classified as basal, PDX67 was HER2-
enriched (Figure 2B, 2C) and PDX118 was luminal B [16]. 
Supporting the close resemblance between original tumors 
and PDXs, samples from each tumor clustered with their 
corresponding PDX models (Figure 2B).
To analyze the effect on tumor growth of inhibiting 
IL-6 signaling, we used two alternative therapies: anti-
IL-6 and anti-IL6RA blocking antibodies. Since the only 
specific receptor of IL-6 is IL6Ralpha, the use of blocking 
antibodies against the cytokine or its cognate receptor 
should be, in principle, functionally equivalent. Thus, we 
used antibodies targeting indistinctly these components. 
Only one of the PDXs (PDX377) showed a tendency 
to respond to the inhibition of IL-6 signaling (Figure 
3A), although the difference did not reach statistical 
significance. This result strongly suggests that only some 
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breast cancers respond to anti-IL-6 therapies, underscoring 
the need of identifying the sensitive tumors, in order to 
save unnecessary treatments.
Analysis of the levels of IL-6 and IL6RA showed 
no significant differences between the sensitive and 
insensitive PDXs (Figure 3B), indicating that the levels 
of expression of these components do not correlate 
with sensitivity to anti-IL-6 therapy. Further, the basal 
levels of phospho-STAT3, the active form of one of the 
main intracellular signals transduced by IL-6 and other 
cytokines [17], did not correlate with responsiveness to 
anti-IL-6 or anti-IL-6RA blocking antibodies (Figure 3). 
Thus, the efficacy of anti-IL-6 therapy cannot be predicted 
by analyzing the absolute levels of the cytokine, its 
cognate receptor or one of its signal transducers.
The efficacy of anti-IL-6 therapies can be gauged 
by functionally analyzing phospho-STAT3
The STAT3 pathway fosters the growth of different 
tumors including those of the breast. Since, in addition 
to IL-6, several cytokines and agonists of G-protein-
coupled receptors (GPCRs) and Toll-like receptors (TLRs) 
Figure 1: Survival outcomes in patients based on PDXs engraftment. Overall survival (upper panel) and progression-free 
survival (medium panel) in patients whose tumors engrafted versus not. Progression-free survival (lower panel) in patients whose tumors 
engrafted versus not, according to their intrinsic subtypes. 
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can activate STAT3 [17], we reasoned that only tumors 
in which the activation of STAT3 depends on IL-6 will 
respond to therapies blocking this cytokine. Thus, we 
aimed to establish a functional assay to determine the 
dependency of STAT3 signaling from IL-6.
Establishing cell cultures directly from human breast 
cancer samples is laborious and inefficient. In addition, 
culture conditions impose a highly selective pressure, 
which results in the expansion of cells particularly fitted 
to grow in vitro. As a consequence much of the original 
intratumoral heterogeneity is lost. In contrast, PDXs retain 
much of this heterogeneity and because of the availability 
of large amounts of tumor material, establishing low-
passage cell cultures is achieved readily. We succeeded 
establishing cultures from 5 out of the 6 PDXs and 
analyzed in vitro the ability of anti-IL-6 to interfere with 
STAT3 activation. Only in cultures from PDXs 118 and 
377, the blocking antibody against IL-6 impaired the 
activation of STAT3 (Figure 4A) indicating that, despite 
expressing detectable levels of IL-6 (Figure 3B), in PDXs 
67 and 154 alternative factors activate this signaling 
pathway.
To confirm this conclusion, we analyzed the levels 
of phospho-STAT3 in samples from the PDXs treated 
as shown in Figure 3A. Confirming the results obtained 
with in vitro cultures, only in the PDX sensitive to anti-
IL-6 signaling therapies, the levels of phospho-STAT3 
decreased with treatment (Figure 4B). In the rest of 
PDXs, autocrine factors maintained or even increased the 
activation of STAT3.
These results show that a functional assay should 
be used to identify breast tumors sensitive to anti-IL-6 
therapy.
Figure 2: Characterization of different breast cancer PDXs. A. The expression of the estrogen receptor (ER), progesterone 
receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 were evaluated in samples from the indicated patient (hu, 
human) and the corresponding PDX (mo, mouse). B. Unsupervised hierarchical clustering of the samples from the original tumor (hu) 
or samples from the corresponding PDXs (mo) according to the levels of expression of 110 selected genes analyzed using the Counter 
platform. All tumors were assigned to an intrinsic molecular type of breast cancer (Luminal A, Luminal B, HER2-enriched, and Basal-
like) [26]. The analyses of PDXs 154, 67 and 50 and PDXs 243 and 377 are presented separately because they were performed in different 
experiments. C. Results of analyses performed as in A and B on the indicated PDXs. Note that the characterization of PDX118 has been 
published elsewhere [16].
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DISCUSSION
Accumulating evidence show the contribution of 
IL-6 to the progression of breast cancers. IL-6 regulates 
normal stem cell self-renewal in the breast and induces 
malignancy in stem cells from human breast carcinoma 
[18]. In addition, IL-6 cooperates with HER2 to promote 
breast cancer [19] and may be involved in the resistance of 
HER2-positive tumors to anti-HER2 therapy [12]. A major 
source of IL-6 in breast tumors are naturally occurring 
senescent cells; inhibition of IL-6 from this source impairs 
the growth of a PDX [14]. Thus, it has been suggested 
that anti-IL-6 therapies, alone or in combination with other 
therapies, may be efficacious to treat breast cancers [20].
Signals transduced by STAT3 are required for 
the progression of different cancers, including those 
of the breast (recently reviewed in [17].). Most of the 
effects of IL-6 are thought to be exerted through STAT3 
but additional factors regulate this signal transducer. 
Therefore, in order to identify tumors sensitive to anti-IL-6 
therapies, it is important to develop functional assays to 
determine in which tumors STAT3 is primarily regulated 
by IL-6.
PDXs recapitulate the architecture as well as the 
molecular and cellular heterogeneity of the tumors from 
which they are derived [1, 21]. In agreement with this view, 
the analysis of the expression of a selected group of genes 
shows the similarity of the PDXs with the tumors from 
which they were derived (Figure 2 and supplementary 
Figure S1) .The reported efficiency of successful 
engraftments of breast cancers in immunodeficient mice 
are highly variable but compared with other tumors, 
is generally low (12-40%) [1,4,6,22,23]. In agreement 
with previous reports, successful engraftment was an 
independent predictor for overall survival and poor 
outcome (Figure 1). Tumors with high proliferation index, 
higher grade and more aggressive behavior have higher 
engraftment rates. In addition, neoadjuvant chemotherapy 
is an independent factor for successful engraftment, 
probably due to the higher aggressiveness of these tumors, 
which responded partially to the treatment, allowing us 
to obtain tissue. Thus, highly aggressive breast tumors 
tend to be overrepresented in PDX collections, advising 
the use of this preclinical model to test novel therapies or 
combinations against life threatening tumors.
Using these models, we have tested the anti-tumor 
efficacy of anti-IL-6 blocking antibodies on patient 
derived xenografts (PDXs) (this report and [14]). The 
fact that four out of six PDXs did not respond to anti-
IL-6 antibodies (Figure 3) highlights the need for reliable 
biomarkers of sensitivity for this treatment. We found no 
significant differences in the levels of IL-6, its cognate 
receptor or phospho-STAT3 in samples from the PDXs 
Figure 3: Effect of therapies against IL-6 signaling on the growth of different breast cancer PDXs. A. PDXs were 
orthotopically implanted into NOD/SCID mice and treated with two anti-IL-6 signaling therapies (anti-IL-6 or anti-IL6RA blocking 
antibodies). Note that, when using anti-IL-6, in order to analyze the role of autocrine IL-6, PDXs were treated with anti-mouse IL-6, 
which does not cross-react with human IL-6 and, thus, does not affect the IL-6 produced by human tumor cells. Anti-IL-6RA antibody 
does not recognize mouse IL-6 receptor [27]. Tumor volumes were determined at the indicated time points and expressed as averages. The 
sensitivity of PDX118 to inhibition of IL-6 signaling has been determined elsewhere [14]. B. Basal levels of IL-6, IL-6RA and phospho-
STAT3 were determined in lysates from the indicated PDX tumors. The results are expressed as averages of three independent tumors ± SD.
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analyzed (Figure 3B), showing that the levels of these 
components do not predict the response to anti-IL-6 
therapy. We hypothesized that only those tumors in which 
the activation of STAT3 relies on IL-6, will respond to 
therapies directed against this cytokine. The analysis of 
cultures obtained from three PDXs and the analysis of 
phospho-STAT3 levels in the PDXs treated with anti-IL-6 
confirmed this hypothesis (Figure 4A).
In summary, our data suggests that only breast 
tumors in which the activation of STAT3 is dependent on 
IL-6 will be sensitive to therapies against this cytokine. 
Since STAT3 can be activated by a variety of cytokines, 
including IL-11, CNTF, LIF and G-CSF [17], in breast 
cancer, it is crucial to identify those tumors that depend 
on IL-6. The use of PDXs, and the cell cultures derived 
from them, is a laborious but feasible procedure to identify 
them.
MATERIALS AND METHODS
Ethics statement
Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and according to national and international 
guidelines and has been approved by the authors’ 
institutional review board.
Patient and tumor material
A total of 137 breast cancer specimens were 
obtained from the operation room and transferred to the 
pathology department where the breast cancer samples 
were collected, transferred to the animal facility and 
implanted into the mice. All the samples were implanted 
during the following 60-90 minutes after surgical removal. 
All patients have signed an informed consent and the 
study was approved by the Ethics Committee of the Vall 
d’Hebron Hospital.
Of samples collected, 136 were primary tumors 
and 1 was an axillary metastasis. The median age was 60 
(range, 24-92). Regarding tumor characteristics, most of 
the tumors were invasive ductal carcinoma (92.7%), grade 
III (59.1%), ER positive (68.6%), PR negative (52.5%), 
HER2 negative (69.3%) and Ki-67 > 20% (80.2%). Half 
of the patients (53.9%) were stage II, while 6 (4.3%) were 
stage IV (Table I).
The proportions of tumors classified by molecular 
subtypes using immunohistochemistry were 10.2% 
Figure 4: Effect of anti-IL-6 on the levels of phospho-STAT3. A. Left, cell cultures established from the indicated PDXs were 
treated with different concentrations of anti-IL-6. Then, cells were lysed and the cell lysates were analyzed by Western blot with the 
indicated antibodies. Right, results from four independent experiments were quantified and expressed as averages ± SD. * P < 0.05 by the 
Student’s t test. B. Left, samples from the indicated PDXs treated as shown in Figure 3 were lysed and analyzed by Western blot with the 
indicated antibodies. Right, results were quantified and expressed as averages ± SD. * P < 0.05 by the Student’s t test.
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luminal A (14 patients), 33.6% luminal B HER2 negative 
(46 patients), 26.3% luminal B HER2 positive (36 
patients), 4.4% HER2 positive (6 patients) and 25.5% 
triple negative (35 patients).
The majority of patients (78.1%) did not receive any 
treatment before surgery, while 21.2% were treated with 
chemotherapy. Six patients (4.4%) were BRCA mutation 
carriers.
Median time to implantation was 3.6 months (range 
1-6). Triple negative tumors grew faster as tumor grafts 
(median time to detection ~2.4 months) than the rest 
(median time to detection ~5 months), in agreement with 
the clinical situation. Engraftment rates in correlation with 
tumor characteristics are summarized in Table 1.
Table 1: Clinical characteristics and corresponding engraftment rates
Tumor Characteristics Engraftment success P value
n (%)
No Yes
Histology
IDC 113 (89) 14 (11) 0.006
ILC 4 (100) 0 (0)  
Metaplasic 0 (0) 3 (100)
Others 3 (100) 0 (0)
Grade
II 55 (98.2) 1 (1.7) 0.001
III 65 (80.2) 16 (19.7)
Estrogen Receptor
Negative 32 (74.4) 11 (25.5) 0.004
Positive 88 (93.6) 6 (6.3)
Progesterone Receptor
Negative 58 (80.5) 14 (19.4) 0.009
Positive 62 (95.3) 3 (4.6)
HER2
Negative 82 (86.3) 13 (13.6) 0.58
Positive 38 (90.4) 4 (9.5)
Ki-67
Low (< 20) 27 (100) 0 (0) 0.02
High (> 20) 93 (84.5) 17 (15.4)
Subtype
Luminal A 14 (100) 0 (0) 0.020
Luminal B HER2 - 43 (93.4) 3 (6.5)
Luminal B HER2 + 33 (91.6) 3 (8.3)
HER2 + 5 (83.3) 1 (16.6)
Triple negative 25 (71.4) 10 (28.5)
Stage
IA 29 (100) 0(0) 0.04
IB 3 (75) 1 (25)
IIA 37 (88.1) 5 (11.9)
IIB 28 (87.5) 4 (12.5)
III 19 (79.1) 5 (20.8)
IV 4 (66.6) 2 (33.3)
BRCA
No 118 (90.08) 13 (9.9) 0.002
Yes 2 (33.3) 4 (66.6)
Neoadjuvant Treatment
NO 99 (92.5) 8 (7.4) 0.002
YES 20 (68.9) 9 (31.03)
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Generation of breast cancer patient-derived 
xenografts and treatments
All the samples were kept and transported in 
DMEM/F12 with 5% FBS (DMEM5) (Invitrogen). 
Three different methods were used to perform the 
implantation: fragments, organoids and single cells. To 
implant fragments, samples were cut in 3 mm3 pieces and 
implanted readily. For organoids and single cells, tissue 
was minced into 1-2 mm3 pieces in a 10 cm Petri dish on 
ice and digested during 1-4 hours (the time was adjusted 
depending on the sample size) in DMEM5 with 2mg/ml 
collagenase IA, at 37ºC in a rotating wheel. The procedure 
was finished when the large pieces of tumor disappeared. 
The solution of digested tumor was diluted 3 times in 
DMEM5 and non-totally digested tissue pieces were 
removed by decantation. The supernatant was serially 
centrifuged to obtain 3 different fractions: fraction A was 
enriched in organoids, fraction B in single epithelial cells, 
stromal cells and blood cells and fraction C in fibroblasts. 
Organoids from fraction A were injected with Matrigel in 
a 1:1 mixture. The cell suspension resulting from mixing 
organoid-depleted fraction A and fraction B was depleted 
from leukocytes, endothelial cells, mesenchymal cells, 
erythroid precursors and macrophages with antibodies 
against CD45, CD31, CD140b, CD235a and CD16 and 
injected with Matrigel.
In all cases, fragments, organoids or single cells 
were implanted in the number four fat pad of six to eight-
week old NOD.CB17PrkdcSCID/J (NOD/SCID) mice 
(Charles River). To do this, mice were anesthetized and 
shaved, the fourth and fifth sets of nipples were localized 
and an inverted Y incision from the midline point between 
the fourth set of nipples was made, ending between the 
fourth and fifth sets to expose the fourth and fifth fat pads 
on one side. After the injection, the animal was sutured 
and analgesics injected. Animals were kept in a clean cage 
with 1 uM 17-β-estradiol-supplemented drinking water. 
Tumor xenografts were measured with callipers every 3 
days and tumor volume was determined using the formula: 
(length x width2) x (pi/6). At the end of the experiment, 
the animals were anesthetized with a 1.5 % isofluorane-air 
mixture and were sacrificed by cervical dislocation.
Anti-human IL-6 (CNT328/Siltuximab, 20 mg/kg in 
sterile PBS) and anti-mouse IL-6 (same dose) were given 
intraperitoneally once weekly from day 0. In the case of 
anti-IL6RA treatment, animals were randomized when 
tumors reached 150 mm3 into control (sterile PBS) and 
treated (tocilizumab, 100 ug per mouse in sterile PBS) 
groups, and treatments were administered intraperitoneally 
3 times per week. 
Mice were maintained and treated in accordance 
with institutional guidelines of Vall d’Hebron University 
Hospital Care and Use Committee.
Immunohistochemical and molecular 
characterization of breast cancers and PDXs
Tumor xenografts were removed, fixed in 4% 
buffered formaldehyde for 24 h and then paraffin-
embedded (FFPE). Sequential 5-um-thick slices were 
then obtained and immunostained for estrogen receptor, 
progesterone receptor, c-erbB2 or Ki-67 (Dako). The same 
procedure was used for human breast cancer samples. 
Diagnosis and histopathological characteristics were 
confirmed by a pathologist.
For each sample, three 2-mm cores enriched with 
tumor tissue were obtained from FFPE tumor blocks. RNA 
was purified using the High Pure FFPE RNA Micro Kit 
(Roche Applied Science) and 100 ng of total RNA was 
used for the Nanostring n-Counter platform to measure 
the expression of 110 selected genes. nCounter raw data 
was log base 2 transformed and normalized using 5 
house-keeping genes (ACTB, MRPL19, PSMC4, RPLP0 
and SF3A1). All tumors were assigned to an intrinsic 
molecular subtype of breast cancer (Luminal A, Luminal 
B, HER2-enriched and Basal-like) or the Normal-like 
breast group using the expression of the 50 PAM50 genes 
and the PAM50 subtype predictor algorithm from Parker 
et al [24].
Cell culture from PDXs
Tumors were disaggregated with 2 mg/ml 
collagenase IA in DMEM5 and 1x105 cells were plated 
over night in six-well plates. Next day, tocilizumab was 
added and cells were harvested and lysed 24 hours later. 
Enzyme-linked ImmunoSorbent assay
Concentration of IL-6 and IL-6R alpha was 
determined in tumor cell lysates according to the 
manufacturer’s instructions.
Protein extraction and immunoblotting
They were performed as described in [25]. Briefly, 
cells were washed twice with ice-cold 1X PBS and 
proteins were extracted with 20 mM Tris-HCl pH 7.4, 
137 mM NaCl, 2 mM EDTA, 10% glycerol, 1% Nonidet 
P-40 supplemented with 50 mg/ml leupeptin, 50 mg/
ml aprotinin, 0.5 mM sodium orthovanadate and 1 mM 
phenylmethylsulfonyl fluoride (Sigma). Breast tumor 
samples were homogenized in the same lysis buffer with 
a Polytron homogeneizer. Protein extracts were quantified 
using bicinchoninic acid protein assay reagent (Pierce), 
resolved by SDS-polyacrylamide gel electrophoresis 
and transferred to nitrocellulose membranes. Primary 
antibodies recognized human specific forms of GAPDH 
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(Abcam) and phospho-STAT3 (Y705) (R&D). Secondary 
antibodies included horseradish peroxidase-linked 
anti-rabbit IgG and anti-mouse IgG (Amersham GE 
Healthcare). Proteins were detected with Immobilon 
western chemiluminescent HRP substrate (Millipore). 
Signals in Western blots were quantified with the software 
ImageJ 1.38 (NIH, Bethesda, MD, USA). 
Statistical analysis
Patient clinical and pathologic tumor characteristics 
were collected. To determine whether the ability of a tumor 
to generate a xenograft might be an indicator of patient 
prognosis, graft data and clinical outcome information was 
also gathered. Results were considered to be statistically 
significant at P < 0.05
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